- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Growth at Reasonable Price
U.S. Pharmaceuticals & Biotech Growth at Reasonable Price
Results
43
43 companies
Incyte
Market Cap: US$12.1b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$63.31
7D
7.3%
1Y
10.9%
Xeris Biopharma Holdings
Market Cap: US$767.1m
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$4.88
7D
-2.6%
1Y
146.5%
Jazz Pharmaceuticals
Market Cap: US$6.5b
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
JAZZ
US$108.98
7D
11.5%
1Y
-0.009%
ANI Pharmaceuticals
Market Cap: US$1.2b
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
ANIP
US$59.99
7D
-9.5%
1Y
-2.3%
Teva Pharmaceutical Industries
Market Cap: US$19.3b
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
TEVA
US$16.94
7D
0.06%
1Y
4.0%
Esperion Therapeutics
Market Cap: US$154.0m
A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
ESPR
US$0.80
7D
0.5%
1Y
-66.0%
Organogenesis Holdings
Market Cap: US$384.4m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$3.08
7D
0.7%
1Y
12.4%